Neurodivergence, together with Consideration Deficit-Hyperactivity Dysfunction (ADHD), stays an space of nice curiosity throughout social media, with excessive ranges of misinformation being unfold on totally different on-line platforms (Carter et al., 2026), as blogged not too long ago by Higson-Sweeney (2026). Regardless of this, there have been no elves running a blog on the remedy of ADHD since our final journey into the woodland earlier this yr (Budgen & Suetani, 2026; Zhang et al., 2025).
To not be discouraged, we’ve returned to debate an thrilling community meta-analysis from Nourredine et al. (2026). Pharmacological remedy is efficient for ADHD, however particular steerage on dosing is restricted. Generally we don’t know if the dose is simply too little or an excessive amount of. On one hand, there’s concern that clinicians could also be participating in therapeutic inertia – prescribing suboptimal doses the place growing could also be more practical. Alternatively, we could danger growing the dose past what’s protected or crucial for maximal efficacy. Earlier dose-effect research examined licensed doses in particular age teams with out a community meta-analysis, that means it was solely attainable to discover direct comparability with placebo.
That is the primary dose-effect community meta-analysis throughout age teams for ADHD. The authors examined a broad dataset, together with information past licensed doses, to estimate efficacy and tolerability throughout dosages and age teams. This research makes an attempt to shed some much-needed gentle on the Goldilocks zone – the doses ‘good’ for folks with ADHD.
Strategies
Eligible articles had been obtained by the MED-ADHD database, a complete repository of double-blind randomised managed trials (RCTs). RCTs with parallel-group or crossover designs utilizing pharmacological monotherapy for a minimum of 1 week had been included. Members had been aged ≥5 with a analysis of ADHD based mostly on Diagnostic and Statistical Handbook of Psychological Problems, Third Version (DSM-III) or later, or equal Worldwide Classification of Illnesses (ICD) standards. Notably, research that mixed pharmacotherapy and psychotherapy had been excluded.
Eligible medicines included amphetamines, atomoxetine, bupropion, clonidine, dexmethylphenidate, guanfacine, methylphenidate, modafinil and viloxazine. The dosages for amphetamines had been transformed to dextroamphetamine-equivalents and methylphenidate was transformed to immediate-release methylphenidate hydrochloride based mostly on the conversion elements from Farhat et al. (2022). The reported doses are the utmost supposed goal dose within the research, not essentially the dose acquired by contributors.
To evaluate the severity of ADHD signs, the authors extracted ranking scale measures (e.g. SNAP or Conners) and expressed these as a standardised imply distinction (SMD). To evaluate tolerability, the danger of dropout was calculated and expressed as an odds ratio (OR). As a result of this was a Bayesian evaluation, uncertainty is reported as 95% credible intervals (CrI) quite than confidence intervals: the vary inside which we may be 95% sure the true impact lies.
Outcomes
15,096 references had been discovered on preliminary screening, with 164 research included within the systematic assessment and 113 research (68 for youngsters and adolescents and 45 for adults) had been included within the community meta-analysis. There have been a complete of 14,138 kids or adolescents with a imply age of 11 (70.6% male) and 11,016 adults with a imply age of 36 (54.0% male). The primary findings are summarised beneath:
Youngsters and Adolescents
Eighteen fixed-dose RCTs with a complete of 4,159 kids or adolescents had been included within the efficacy evaluation. The tolerability evaluation included information from 65 RCTs with a complete of 13,972 people.
- Methylphenidate reached peak efficacy at 45mg/day (SMD −0.89; 95% CrI −1.18 to −0.60).
- Most danger of discontinuation was 2.7% (95% CrI 1.4 to five.1) at 50mg/day. Apparently, growing the dose past the licensed most didn’t increase the discontinuation danger, however precision was low.
- Amphetamines reached peak efficacy at 25mg/day (SMD -1.06; 95% CrI -1.35 to -0.78).
- There was a linear discontinuation danger with the danger exceeding placebo at doses above 25mg/day.
- Lisdexamfetamine was separated with a peak efficacy at roughly 55mg/day (SMD -1.05; 95% CrI -1.4 to -0.69). Primarily based on the conversion elements, that is roughly equal to 25mg/day of amphetamines.
- Guanfacine reached peak efficacy at 4mg/day (SMD -0.66; 95% CrI -0.99 to -0.31)
- Discontinuation danger elevated as much as 4mg/day, reaching a median danger of 9.8% (95% CrI 4.4 to twenty). Though the danger appeared to lower following this, with very low certainty.
Inclusion of flexible-dose trials yielded comparable outcomes. These trials included information for dosing at an equal 93mg/day methylphenidate with a urged decline in efficacy.
Adults
11 fixed-dose RCTs with 2,450 people included within the efficacy evaluation. The tolerability evaluation included information from 42 RCTs with a complete of 10,463 adults.
- Amphetamines reached a plateau at 50mg/day (SMD -0.74; 95% CrI -1.26 to -0.2).
- Observe that the utmost licensed dose by the FDA is 40mg/day
- Threat of discontinuation exceeded placebo (2.6%; 95% CrI 1.8 to three.6) at 50mg/day and continued to extend with dose.
- Methylphenidate efficacy appeared to extend with escalating doses, however there have been marginal good points above roughly 50mg/day.
- Threat of discontinuation exceeded placebo at 50mg/day
- On the most FDA licensed dose of 60mg, the danger of discontinuation elevated to 7.3% (95% CrI 4.3 to 12).
Inclusion of flexible-dose trials expanded the dataset to five,025 adults, and the dose-effect profiles remained unchanged, albeit with narrower credible intervals.
Conclusions
The authors concluded:
Our findings problem each therapeutic inertia — accepting suboptimal response with out additional dose titration — and uncritical dose escalation past licensed limits, when potential harms outweigh anticipated advantages.
Strengths and limitations
There are various strengths on this research as a result of its strong design. Most significantly, the inclusion standards had been rigorous within the requirement for double-blind RCT research with analysis of ADHD based mostly on recognised requirements (DSM & ICD) and a deal with fixed-dose trials. This slim definition has resulted in a inhabitants much less reflective of these seen in medical settings. Nevertheless, it’s an acceptable start line to cut back the danger of bias and help within the interpretation of outcomes. Whereas many included trials had a excessive danger of bias, sensitivity evaluation excluding these didn’t change the outcomes, supporting the robustness of the findings.
The authors determine a number of limitations with their research and talk about the restricted vary of doses (significantly in grownup research), heterogeneous ranking scales for efficacy, lack of capability to conduct subgroup analyses, incapacity to evaluate the influence of severity, quick period of research and restricted generalisability to medical populations. Particularly, the authors stress that the outcomes from the research are legitimate at a bunch degree, however shouldn’t be used to tell decision-making on the particular person affected person degree as a result of variability in response to medicines. We might spotlight the quick durations of the included research (a imply of seven weeks for adults) as a distinguished limitation of this paper. ADHD is a lifelong situation, and many individuals select to proceed pharmacological remedy long-term. Hostile results with long-term use of psychostimulants usually are not effectively outlined, significantly for adults, the place there shall be growing issues for cardiovascular uncomfortable side effects with longer use at increased doses. These dangers usually are not captured within the included research as a result of quick durations.
We additionally stress the constraints as a result of comparatively restricted information for adults. There have been far fewer people within the grownup evaluation compared to kids and adolescents, leading to much less precision within the dose-effect curves, with widening credible intervals at increased doses. Particularly, the amphetamine dose-effect evaluation consisted of information from 459 people, with virtually half (225) receiving a dosage above 40mg/day dextroamphetamine-equivalent. If there have been extra people included within the evaluation, it will be attention-grabbing to see how the dose-effect curves would change and if these would mirror the U-shaped curves seen within the youngster and adolescent cohort. Using dose conversion to dextroamphetamine-equivalents was crucial as a result of restricted dataset; nevertheless, the conversions could have affected the outcomes, as totally different formulations could not have comparable efficacy at these doses. It also needs to be famous that of the 459 people uncovered to amphetamines, 437 acquired blended amphetamine salts in an extended-release formulation and 22 acquired dextro-amphetamine in a direct launch formulation. No people acquired lisdexamfetamine or dexamfetamine; two medicines generally prescribed in Australia.
Implications for observe
This research builds on the dose-effect responses seen within the meta-analyses by Farhat et al. (2022 & 2024) by incorporating oblique proof with the methodology of a community meta-analysis. The outcomes are fascinating and problem frequent medical observe the place prescribers could cease growing dosages when gentle adversarial results are encountered, probably lacking out on peak efficacy. Concurrently, it cautions towards venturing too far into the hazard zone, prescribing increased doses that could not present elevated profit for folks with ADHD. Many medical tips are likely to assist an individualised strategy of accelerating dosages so long as there’s symptom enchancment and no insupportable adversarial results. This research provides to this by discovering that additional will increase past 45mg for methylphenidate and 25mg for amphetamines are unlikely to convey profit and should in actual fact enhance the danger of hurt. For adults, the same dose-dependent enhance in efficacy is seen, reaching a plateau at roughly 50mg for each methylphenidate and amphetamines, with growing dangers past this. Notably, the dose of amphetamines is above the FDA-licensed most dose, probably elevating the notion that doses above these licensed for amphetamines could convey elevated profit on the inhabitants degree.
This research takes a step additional in the direction of a higher understanding of efficient dosing within the remedy of ADHD. In beginning to outline the response throughout doses, we’re shifting a lot nearer in the direction of the aim of knowledgeable prescribing and observe. How distant are we from having clear tips akin to these for antidepressants and antipsychotics with outlined minimal efficient doses and urged limits above which there’s unlikely to be profit for many sufferers? Now we have a wealth of this info for different psychotropic medicines; it’s time that we develop this for ADHD medicines.
At an area degree, in Australia, it’s tough to know the way to translate this information into observe, significantly for adults. Right here, lisdexamfetamine is the second mostly prescribed psychostimulant (AIHW, 2025). Changing the outcomes from this research, maximal efficacy could also be seen with lisdexamfetamine at roughly 110mg. This dose is much past the 70mg most authorized in most jurisdictions in Australia (AADPA, 2026). Ought to we then be growing the dosage for all adults, so far as tolerated, to the utmost allowed? At this stage, the proof doesn’t assist this observe, given the clear lack of long-term tolerance information in adults and the absence of lisdexamfetamine formulations within the evaluation.
In the end, this research from Nourredine et al. (2026) paves a brand new path in the direction of growing precision with ADHD pharmacological administration and will increase our information of efficient dosing. Additional analysis is now wanted to deal with the gaps in long-term tolerance and to offer extra information throughout a broader vary of medicines and doses. Someday sooner or later, we hope that will probably be simpler to search out the remedy dose ‘good’ for folks with ADHD with out the necessity for trial and error like Goldilocks trying to find her porridge.
Assertion of pursuits
Jordan Budgen has no conflicting pursuits with respect to the content material of this weblog put up.
Shuichi Suetani is a member of the Royal Australian and New Zealand School of Psychiatrists ADHD Community, and Australasian ADHD Professionals Affiliation.
Hyperlinks
Major paper
Mikail Nourredine, Lucie Jurek, Tasnim Hamza, Andrea Cipriani, Fabien Subtil, Valeria Parlatini, Luis Farhat, Guilherme Fusetto Veronesi, Orestis Efthimiou, Georgia Salanti, Samuele Cortese (2026) Pharmacological interventions for ADHD: a scientific assessment and dose–impact community meta-analysis. The Lancet Psychiatry, 13, 485-495.
Different references
Australasian ADHD Professionals Affiliation (AADPA) (2026). ADHD Medicine Prescribing Rules & Authorities in Australia & New Zealand.
Australian Institute of Well being and Welfare (AIHW) (2025). ADHD Medicines disbursed 2004-05 to 2023-24.
Budgen J & Suetani S. Medicine influence on non-core ADHD signs and hurt prevention. The Psychological Elf, 21 Jan 2026.
Farhat L.C., Flores J.M., Behling E. et al. (2022) The consequences of stimulant dose and dosing technique on remedy outcomes in attention-deficit/hyperactivity dysfunction in kids and adolescents: a meta-analysis. Mol Psychiatry 27, 1562–1572.
Farhat, L. C., Flores, J. M., Avila-Quintero, V. J., Polanczyk, G. V., Cipriani, A., Furukawa, T. A., Bloch, M. H., & Cortese, S. (2024). Therapy Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Consideration-Deficit/Hyperactivity Dysfunction: A Systematic Evaluate and Meta-Evaluation. JAMA psychiatry, 81(2), 157–166.
Higson-Sweeney N. Scrolling for solutions: how dependable is psychological well being and neurodivergence-related info on social media? – Nationwide Elf Service. The Psychological Elf, 22 Apr 2026.
